Sanofi to continue fight against generic Lovenox

* To continue suit on FDA approval of generic clot preventer

* Says injunction refusal did not comment on merit of suit

LONDON, Aug 26 (BestGrowthStock) – French drugmaker Sanofi-Aventis
(SASY.PA: ) said it would continue a legal battle in the United
States against a generic version of its blood clot preventer
Lovenox, despite a court rebuff.

“The company’s case against the FDA (Food and Drug
Administration) will continue to move forward, even without
preliminary injunctive relief,” Sanofi said in a statement
released on Thursday.

U.S. District Judge Emmet Sullivan on Wednesday refused to
issue a preliminary injunction after a request by Sanofi to
block the generic version of Lovenox that is already being sold
by Novartis’s (NOVN.VX: ) Sandoz unit and Momenta (MNTA.O: ).

The FDA approved the generic blood thinner in July despite
concerns by Sanofi that the agency failed to follow its
procedures or ensure the generic drug had the same active
ingredient as Lovenox — a complex injectable drug that Sanofi
argues is hard to replicate accurately.

Judge Sullivan said in his decision that an injunction would
serve the public interest only if Sanofi was likely to succeed
in proving the FDA had exceeded its authority in granting Sandoz
approval to sell the generic drug.

But Sanofi noted that the court had not ruled on the merits
its suit against the FDA.

Lovenox was Sanofi’s second-biggest drug worldwide last year
with sales of some $4 billion, 60 percent of which was in the
United States.

It is one of a number of key drugs facing generic
competition — one factor behind the drive by Sanofi Chief
Executive Chris Viehbacher to find new sources of growth via
acquisitions, including a potential deal for Genzyme (GENZ.O: ).

Viehbacher sent a takeover proposal valuing Genzyme at about
$18.4 billion to Genzyme on Aug. 3 but the two sides are still
far apart on price, according to sources familiar with the
situation.
(Reporting by Ben Hirschler; Editing by Karen Foster)

Sanofi to continue fight against generic Lovenox